Tandem Diabetes (TNDM) Reaches a 52-Week High on Strong Prospects

0
4
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Quotes from the action of Tandem Diabetes Care, Inc. TNDM reached a new high of 52 weeks at $ 74.37 on March 13, closing nominally at $ 71.42. In the last six months, the company has gained 39.6%.

The market capitalization of the stock is $ 4.12 billion.

In addition, the trend of revision of Tandem's estimates for the current quarter is favorable. In the last 30 days, two estimates have increased, but none has decreased. As a result, estimates went from a loss of 35 cents per share to a loss of 28 cents.

The company's five-year historical growth rate is also favorable, at 35% compared to 27.1% of the sector and 3.9% of the S 500.

Tandem currently has a rank of Zacks # 3 (pending).

Growth factors

Product launches continue: In the last quarter published, the insulin pump has been licensed in Canada. In addition, the FDA has classified the t: slim X2 as a new category of device called infusion pumps with replacement controller. This category is & nbsp; called ACE pumps and is related to the FDA interoperability initiative. "data-reactid =" 11 "> Stock price of Tandem Diabetes Care, Inc. TNDM reached a new high of 52 weeks at $ 74.37 on March 13, closing nominally at $ 71.42. In the last six months, the company has gained 39.6%.

The market capitalization of the stock is $ 4.12 billion.

In addition, the trend of revision of Tandem's estimates for the current quarter is favorable. In the last 30 days, two estimates have increased, but none has decreased. As a result, estimates went from a loss of 35 cents per share to a loss of 28 cents.

The company's five-year historical growth rate is also favorable, reaching 35%, compared to 27.1% for the sector and 3.9% for the S & P 500.

Tandem currently has a rank of Zacks # 3 (pending).

Growth factors

Product launches continue: In the last quarter published, the insulin pump has been licensed in Canada. In addition, the FDA has classified the t: slim X2 as a new category of device called infusion pumps with replacement controller. This category is called ACE pump and is related to the FDA interoperability initiative.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Tandem Diabetes Care, Inc. Awards"data-reactid =" 12 ">Tandem Diabetes Care, Inc. Awards

Tandem Diabetes Care, Inc. Award | Tandem Diabetes Care, Inc. Quote

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The market is optimistic about the Tandem project to launch a mobile application in the first half of 2019. The app will use the Bluetooth radio capability to wirelessly download pump data to t: connect, receive notification of pump alerts and alarms, as well as integrate other related information health from third-party sources.

The company plans to use its remote software update tool, Tandem Device Updater, to address a Control IQ technology issue that was identified during the ongoing DCLP3 phase of the International Diabetes Closed Loop clinical trial. IDCL).

Strong product shipment: One of the key drivers of Tandem's growth over the last two quarters has been the successful deployment of t: slim X2 with Basal-IQ technology. This new-generation insulin pump has enjoyed robust sales in domestic and international markets. This has boosted supply capacity and sales renewal, strengthening the core business of the company. In the third and fourth quarters, Tandem's pump shipments increased 118% and 133% year-over-year. Domestic sales of Animas insulin pumps hit an all-time high in the fourth quarter.

International distribution drives growth: In 2018, the company has signed agreements with Australasian Medical & amp; Scientific Ltd (AMSL) and New Zealand Medical & amp; Scientific Ltd (NZMS) will distribute insulin pump products in Australia and New Zealand. Around the same time, Tandem teamed up with Movi SpA for the marketing of t: slim X2 in Italy.

Unique pump platforms, high-end customer service, automated insulin dispensing programs and international expansion are also expected to fuel Tandem's growth.

Choice of keys

ABIOMED, ​​Inc., ABMD, Penumbra, Inc., PEN and Masimo, Inc., MASI, are among the top ranked titles in the medical space. Notably, each of these actions currently carries the Zacks Rank # 2 (Buy). You can see You will find here the complete list of Zacks actions n ° 1 of the current rank (strong purchase)."data-reactid =" 22 "> The market is optimistic about the Tandem project to launch a mobile application in the first half of 2019. The application will use Bluetooth radio capacity to wirelessly download pump data on t: connect, receive notification of pump alerts and alarms, as well as integrate other health information from third-party sources.

The company plans to use its remote software update tool, Tandem Device Updater, to address a Control IQ technology issue that was identified during the ongoing DCLP3 phase of the International Diabetes Closed Loop clinical trial. IDCL).

Strong product shipment: One of the key drivers of Tandem's growth over the last two quarters has been the successful deployment of t: slim X2 with Basal-IQ technology. This new-generation insulin pump has enjoyed robust sales in domestic and international markets. This has boosted supply capacity and sales renewal, strengthening the core business of the company. In the third and fourth quarters, Tandem's pump shipments increased 118% and 133% year-over-year. Domestic sales of Animas insulin pumps hit an all-time high in the fourth quarter.

International distribution drives growthIn 2018, the company signed agreements with Australasian Medical & Scientific Ltd. (AMSL) and New Zealand Medical & Scientific Ltd. (NZMS) for the distribution of insulin pump products in Australia and New Zealand. Around the same time, Tandem teamed up with Movi SpA for the marketing of t: slim X2 in Italy.

Unique pump platforms, high-end customer service, automated insulin dispensing programs and international expansion are also expected to fuel Tandem's growth.

Choice of keys

ABIOMED, ​​Inc., ABMD, Penumbra, Inc., PEN and Masimo, Inc., MASI, are among the top ranked titles in the medical space. Notably, each of these actions currently carries the Zacks Rank # 2 (Buy). You can see You will find here the complete list of Zacks actions n ° 1 of the current rank (strong purchase).

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The growth rate of long-term profits of ABIOMED is expected at 27.67%.

Penumbra's long-term earnings growth rate is estimated at 20.93%.

The long-term profits of Masimo are expected to increase by 15.60%.

The best stocks of today's Zacks

Would you like to see the updated choices of our best winning strategies on the market? From 2017 to 2018, while the S & P 500 gained + 15.8%, five of our screens were + 38.0%, + 61.3%, + 61.6%, + 68.1% and + 98 , 3%. This outperformance is not a recent phenomenon. From 2000 to 2018, while the S & P averaged + 4.8% annually, our main strategies averaged 56.2% a year. "Data-reactid =" 23 "> ABIOMED's long-term earnings growth rate is expected at 27.67%.

Penumbra's long-term earnings growth rate is estimated at 20.93%.

The long-term profits of Masimo are expected to increase by 15.60%.

The best stocks of today's Zacks

Would you like to see the updated choices of our best winning strategies on the market? From 2017 to 2018, while the S & P 500 index gained + 15.8%, five of our screens were up + 38.0%, + 61.3%, + 61.6%, + 68.1 % and + 98.3%. This outperformance is not a recent phenomenon. From 2000 to 2018, while the S & P index averaged + 4.8% per annum, our main strategies averaged 56.2% a year.

The story continues